Back

Akari Therapeutics expands IP portfolio with PCT filing for cancer ADC payload

Verifying
  • Akari Therapeutics filed a PCT application covering an ADC payload.
  • The filing concerns a payload related to RNA splicing in cancers.
  • Akari Therapeutics described the filing as an expansion of its intellectual property portfolio.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.